Multiple Sclerosis Trial, Recruiting NCT06715436 Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT06715436
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with relapsing-remitting MS (a type of MS with flare-ups and periods of recovery) or progressive MS (a type that gradually worsens over time)
  • People aged between 18 and 60 years
  • People whose body weight falls within a moderate range (BMI between 18.5 and 39.9)
  • People who are either not taking any MS medications, or who have been on a stable MS medication for at least 6 months
  • People who are able to give verbal and written consent to participate

Who may not be able to join:

  • People who are currently following a weight loss program or a specific diet (such as vegetarian or vegan), people who are not willing to follow the diet assigned by the trial, or people who already closely follow a Mediterranean-style diet
  • People who are pregnant or breastfeeding
  • People who have had an MS relapse (flare-up) or received cortisone treatment within the 30 days before joining the study
  • People with significant ongoing health conditions such as serious metabolic disorders, progressive diseases, or cancer
  • People taking more than 1 gram per day of omega-3 fatty acid supplements
  • People who are underweight or severely obese
  • People with significant difficulties in thinking, understanding, or cooperating
  • People with type 1 (insulin-dependent) diabetes
  • People who have lost more than 5 kg in the 2 months before joining the study
  • People who have been diagnosed with, or are suspected of having, an eating disorder
  • People with a history of kidney stones
  • People taking blood-thinning medication (oral anticoagulants)
  • People with a known history of alcohol or drug misuse

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Eleonora Tavazzi, MD, U.O. Sclerosi Multipla

Phone: 0382380385

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Registry
ClinicalTrials.gov
Start date
15 March 2024
Est. completion
15 March 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

The CPH subscale of the Multiple Sclerosis Quality of Life-54 (MSQoL -54)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov